857 results match your criteria: "Guangdong Esophageal Cancer Institute; Sun Yat-sen University Cancer Center[Affiliation]"

Background: Early detection of cancer remains an unmet need in clinical practice, and high diagnostic sensitivity and specificity biomarkers are urgently required. Here, we attempted to identify secreted proteins encoded by super-enhancer (SE)-driven genes as diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC).

Methods: We conducted an integrative analysis of multiple data sets including ChIP-seq data, secretome data, CCLE data and GEO data to screen secreted proteins encoded by SE-driven genes.

View Article and Find Full Text PDF

Radiomics Nomogram with Added Nodal Features Improves Treatment Response Prediction in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Study.

Ann Surg Oncol

December 2023

Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China.

Article Synopsis
  • The study aimed to create a radiomics nomogram to help predict the pathological complete response (pCR) to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma (ESCC).
  • Using a multicenter retrospective approach, researchers developed three radiomics models based on tumor and lymph node features, integrating these with clinicoradiological factors to assess their predictive power.
  • Results showed that the radiomics nomogram was more effective than existing models in predicting pCR, suggesting that radiomic features from lymph nodes can significantly enhance treatment decision-making for ESCC patients.
View Article and Find Full Text PDF

Lysosomal cyst(e)ine storage potentiates tolerance to oxidative stress in cancer cells.

Mol Cell

October 2023

Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Guangdong Esophageal Cancer Institute, Guangzhou 510060, China. Electronic address:

Cyst(e)ine is a key precursor for the synthesis of glutathione (GSH), which protects cancer cells from oxidative stress. Cyst(e)ine is stored in lysosomes, but its role in redox regulation is unclear. Here, we show that breast cancer cells upregulate major facilitator superfamily domain containing 12 (MFSD12) to increase lysosomal cyst(e)ine storage, which is released by cystinosin (CTNS) to maintain GSH levels and buffer oxidative stress.

View Article and Find Full Text PDF

ASO Author Reflections: Can Nodal Features Improve Treatment Response Prediction in Esophageal Cancer?

Ann Surg Oncol

December 2023

Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China.

View Article and Find Full Text PDF

Background: As one of the most common malignancies, esophageal cancer has two subtypes, squamous cell carcinoma and adenocarcinoma, arising from distinct cells-of-origin. Distinguishing cell-type-specific molecular features from cancer-specific characteristics is challenging.

Results: We analyze whole-genome bisulfite sequencing data on 45 esophageal tumor and nonmalignant samples from both subtypes.

View Article and Find Full Text PDF

Introduction: The tumor-associated microbiota plays a vital role in cancer development. Accumulating evidence shows that Fusobacterium nucleatum (Fn) participates in the progression of multiple tumor types. However, the underlying mechanisms remain unclear.

View Article and Find Full Text PDF

Background: Two staging systems, the 8th staging system by the American Joint Committee on Cancer (AJCC) and the 11th Japanese classification by Japan Esophageal Society (JES), are currently applied in the clinic for predicting the prognosis of patients with esophageal squamous cell carcinoma (ESCC). The differences between the two staging systems have been widely researched. However, little studies focus on the differences in specific staging between the two systems.

View Article and Find Full Text PDF

A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal.

Signal Transduct Target Ther

August 2023

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P.R. China.

Immune checkpoint inhibitors (ICIs) have induced durable clinical responses in a subset of patients with colorectal cancer (CRC). However, the dis-satisfactory response rate and the lack of appropriate biomarkers for selecting suitable patients to be treated with ICIs pose a major challenge to current immunotherapies. Inflammation-related molecule A20 is closely related to cancer immune response, but the effect of A20 on "eat-me" signal and immunotherapy efficacy remains elusive.

View Article and Find Full Text PDF

Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.

Cell Rep Med

August 2023

Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China. Electronic address:

Article Synopsis
  • NY-ESO-1-specific T cell receptor therapy (TCR-T) is showing promise in treating tumors that express the NY-ESO-1 antigen, but current protocols need improvement for safety and effectiveness.
  • A phase 1 clinical trial tested TCR affinity-enhanced specific T cell therapy (TAEST16001) on 12 patients, following a regimen of lymphodepleting chemotherapy and low-dose IL-2 injections.
  • Results showed no serious adverse events, a 41.7% overall response rate, a median progression-free survival of 7.2 months, and a median duration of response of 13.1 months, indicating that TAEST16001 could be a safe and effective option for advanced soft tissue
View Article and Find Full Text PDF

Elevated levels of neutrophil related chemokine citrullinated histone H3, interleukin-8 and C-reaction protein in patients with immune checkpoint inhibitor therapy: predictive biomarkers for response to treatment.

Cancer Cell Int

August 2023

Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China.

Background: Immune checkpoint inhibitor (ICI) therapy has been used in various tumors. The biomarkers predictive of a response to ICI treatment remain unclear, and additional and combined biomarkers are urgently needed. Secreted factors related to the tumor microenvironment (TME) have been evaluated to identify novel noninvasive predictive biomarkers.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess how effective and safe toripalimab is when used alongside neoadjuvant chemoradiotherapy (NCRT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
  • Conducted as a phase II trial with 44 patients, the research found that 50% of participants achieved a pathological complete response (pCR), but this was not significantly better than the historical control group. The R0 resection rate was very high at 98%.
  • Despite showing promising signs of efficacy and a manageable safety profile, the authors suggest that more extensive phase III trials are needed to fully evaluate the benefits of this treatment combination.
View Article and Find Full Text PDF

Cuproptosis and associated immune-related genes (IRG) have been implicated in tumorigenesis and tumor progression. However, their effects on lung adenocarcinoma (LUAD) have not been elucidated. Therefore, we investigated the impact of cuproptosis-associated IRGs on the immunotherapy response and prognosis of LUAD using a bioinformatical approach and in vitro experiments analyzing clinical samples.

View Article and Find Full Text PDF

Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a phase 1b trial of neoadjuvant PD-L1 blockade with adebrelimab in resectable ESCC. Patients received two neoadjuvant doses of adebrelimab followed by surgery.

View Article and Find Full Text PDF

NAT10-mediated ac4C tRNA modification promotes EGFR mRNA translation and gefitinib resistance in cancer.

Cell Rep

July 2023

Department of Otolaryngology, Center for Translational Medicine, Precision Medicine Institute, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. Electronic address:

Aberrant RNA modifications are frequently associated with cancers, while the underlying mechanisms and clinical significance remain poorly understood. Here, we find that the ac4C RNA acetyltransferase NAT10 is significantly upregulated in esophageal cancers (ESCAs) and associated with poor ESCA prognosis. In addition, using ESCA cell lines and mouse models, we confirm the critical functions of NAT10 in promoting ESCA tumorigenesis and progression in vitro and in vivo.

View Article and Find Full Text PDF

Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance.

Cell Discov

July 2023

Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Posttranslational modification dramatically enhances protein complexity, but the function and precise mechanism of novel lysine acylation modifications remain unknown. Chemoresistance remains a daunting challenge to successful treatment. We found that lysine butyrylation (Kbu) is specifically upregulated in chemoresistant tumor cells and tissues.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness and safety of various treatment options for advanced esophageal cancer, including immunotherapy, immunochemotherapy, chemotherapy, and targeted therapy, focusing on their performance as initial treatments.
  • Data was collected from clinical trials published until May 2022, utilizing a network meta-analysis approach to compare outcomes like overall survival, progression-free survival, and adverse events among the different regimens.
  • The findings, which are still pending, aim to provide insight into the relative strengths of these therapies, with detailed statistical analyses that could influence treatment decisions for patients with metastatic esophageal cancer.
View Article and Find Full Text PDF

Dissecting T-cell heterogeneity in esophageal squamous cell carcinoma reveals the potential role of LAIR2 in antitumor immunity.

Clin Exp Immunol

December 2023

Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.

Esophageal squamous cell carcinoma (ESCC), one of the most commonly diagnosed and lethal malignant diseases, has a complex tumor ecosystem. An obvious requirement for T-cell-mediated tumor control is the infiltration of tumor-reactive T cells into the tumor. Here, we obtained detailed T-cell compositions in both ESCC tumors and matched peripheral blood mononuclear cells (PBMCs) at single-cell resolution.

View Article and Find Full Text PDF

Targeting LncRNA with antisense oligonucleotide inhibits malignancy of esophageal squamous cell carcinoma cells and .

Oncol Res

July 2023

School of Public Health, International Cancer Center, Guangdong Key Laboratory for Genome Stability & Disease Prevention, Shenzhen University Medical School, Shenzhen, China.

Accumulating evidence has indicated that long non-coding RNAs (lncRNAs) play critical roles in the development and progression of cancers, including esophageal squamous cell carcinoma (ESCC). However, the mechanisms of lncRNAs in ESCC are still incompletely understood and therapeutic attempts for targeting cancer-associated lncRNA remain a challenge. By RNA-sequencing analysis, we identified that was a novel ESCC-associated lncRNA.

View Article and Find Full Text PDF

Salivary Extracellular MicroRNAs for Early Detection and Prognostication of Esophageal Cancer: A Clinical Study.

Gastroenterology

October 2023

Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China; Department of General Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China; Institute of Precision Cancer Medicine and Pathology, School of Medicine, Minister of Education Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China. Electronic address:

Background & Aims: Early detection of esophageal squamous cell carcinoma (ESCC) will facilitate curative treatment. We aimed to establish a microRNA (miRNA) signature derived from salivary extracellular vesicles and particles (EVPs) for early ESCC detection and prognostication.

Methods: Salivary EVP miRNA expression was profiled in a pilot cohort (n = 54) using microarray.

View Article and Find Full Text PDF

ASO Author Reflections: Overall Quality of Life was Comparable for Patients with Intrathoracic Anastomosis and Those with Cervical Anastomosis After Esophagectomy.

Ann Surg Oncol

November 2023

Department of Thoracic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong Province, China.

View Article and Find Full Text PDF

Background: Two cycles of neoadjuvant PD-1 blockade plus chemotherapy induced favorable pathological response and tolerant toxicity in patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, approximately 25% of patients relapsed within 1 year after surgery, indicating that a short course of treatment may not be sufficient. Therefore, exploring the effects of intensive treatment is needed for optimal clinical outcomes.

View Article and Find Full Text PDF

Control of SOX2 protein stability and tumorigenic activity by E3 ligase CHIP in esophageal cancer cells.

Oncogene

July 2023

Shanghai Key Laboratory of Regulatory Biology, Fengxian District Central Hospital-ECNU Joint Center of Translational Medicine, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.

Article Synopsis
  • SOX2, a protein linked to tumor initiation and function in various squamous cell carcinomas, including esophageal cancer, is often overexpressed, but the reasons for this are not fully understood.
  • The study discovered that CHIP, a regulator associated with protein stability, negatively affects SOX2 levels by promoting its degradation with help from another protein, HSP70.
  • In esophageal tumors, CHIP is mostly found in the cytoplasm instead of the nucleus, which could lead to increased SOX2 levels, and targeting HSP90 could be a potential treatment for cancers expressing high SOX2.
View Article and Find Full Text PDF

Role of breastfeeding on maternal and childhood cancers: An umbrella review of meta-analyses.

J Glob Health

June 2023

Foshan Fetal Medicine Research Institute, Affiliated Foshan Women and Children Hospital, Southern Medical University, Foshan, Guangdong, China.

Background: Multiple studies and meta-analyses have claimed that breastfeeding is inversely correlated with maternal and childhood cancers. These results could either be causal or confounded by shared risk factors. By conducting an umbrella review, we aimed to consolidate the relationship between breastfeeding and maternal and childhood cancers.

View Article and Find Full Text PDF

GSK3β-driven SOX2 overexpression is a targetable vulnerability in esophageal squamous cell carcinoma.

Oncogene

July 2023

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.

Esophageal squamous cell carcinoma (ESCC) is one of the deadliest forms of human malignancy that currently lacks approved targeted therapeutics. Accumulating evidence suggests that SOX2 overexpression is a key driving factor for ESCC and various squamous cell carcinoma. Here, through screening a small-molecule kinase inhibitor library, we identified GSK3β as a kinase that is critically required for robust SOX2 expression in ESCC cells.

View Article and Find Full Text PDF